Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(13):1088-1091; doi:10.1093/jnci/92.13.1088
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Werness, B. A.
Right arrow Articles by Piver, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Werness, B. A.
Right arrow Articles by Piver, M. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 13, 1088-1091, July 5, 2000
© 2000 Oxford University Press

REPORTS

Ovarian Carcinoma In Situ With Germline BRCA1 Mutation and Loss of Heterozygosity at BRCA1 and TP53

Bruce A. Werness, Pankhuri Parvatiyar, Susan J. Ramus, Alice S. Whittemore, Kim Garlinghouse-Jones, Ingrid Oakley-Girvan, Richard A. DiCioccio, Jonathan Wiest, Yoshiaki Tsukada, Bruce A. J. Ponder, M. Steven Piver

Affiliations of authors: B. A. Werness, P. Parvatiyar (Department of Pathology), J. Wiest (Department of Environmental Health), University of Cincinnati Medical Center, OH; S. J. Ramus, B. A. J. Ponder, Department of Oncology, University of Cambridge, U.K.; A. S. Whittemore, K. Garlinghouse-Jones, I. Oakley-Girvan, Department of Health Research and Policy, Stanford University Medical Center, CA; R. A. DiCioccio (Department of Cancer Genetics), M. S. Piver (The Gilda Radner Familial Ovarian Cancer Registry), Roswell Park Cancer Institute, Buffalo, NY; Y. Tsukada, Sisters Hospital, Buffalo.

Correspondence to: Bruce A. Werness, M.D., Department of Pathology, University of Cincinnati Medical Center, 231 Bethesda Ave., Cincinnati, OH 45267 (e-mail: bruce.werness{at}uc.edu).

Background: The two-hit hypothesis for the genesis of cancer predicts that cancer can develop when the wild-type allele of a tumor suppressor gene is lost in an individual with a germline mutation in that gene. Neither loss of heterozygosity (LOH) for BRCA1 nor mutations of the TP53 (also known as p53) gene have been documented prior to invasion in ovarian cancers arising in women with germline BRCA1 mutations. Such documentation is difficult because lesions are rarely identified in ovarian epithelium. We, therefore, looked for LOH at microsatellite polymorphisms linked to the BRCA1 and TP53 tumor suppressor loci in an incidental carcinoma in situ of the ovary removed prophylactically from a woman with a germline BRCA1 mutation. Methods: By use of laser-capture microdissection, we obtained pure populations of atypical ovarian epithelial cells and normal stromal cells. DNA was extracted, amplified with primers flanking polymorphic microsatellites linked to BRCA1 (D17S855 and D17S579) and TP53 (TP53 and D17S786), and analyzed for LOH at these microsatellites. We also tested for p53 expression in the abnormal epithelium by immunohistochemistry. Results: Both of the markers linked to TP53 showed LOH, as did an intragenic BRCA1-linked marker (D17S855). The other microsatellite marker for BRCA1 was uninformative. Immunohistochemical staining with an antibody to p53 showed strong immunoreactivity confined to the atypical epithelium. Conclusions: BRCA1, as well as TP53, can undergo LOH prior to stromal invasion in BRCA1-associated ovarian cancer. Strong immunoreactivity for p53 suggests the presence of mutated p53 in these cells as well. These findings suggest that loss of function of these two tumor suppressor genes occurs early in ovarian carcinogenesis in BRCA1 mutation carriers.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Endocr. Rev.Home page
M. A. Edson, A. K. Nagaraja, and M. M. Matzuk
The Mammalian Ovary from Genesis to Revelation
Endocr. Rev., October 1, 2009; 30(6): 624 - 712.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. I. Weberpals, K. V. Clark-Knowles, and B. C. Vanderhyden
Sporadic Epithelial Ovarian Cancer: Clinical Relevance of BRCA1 Inhibition in the DNA Damage and Repair Pathway
J. Clin. Oncol., July 1, 2008; 26(19): 3259 - 3267.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Xing and S. Orsulic
A mouse model for the molecular characterization of brca1-associated ovarian carcinoma.
Cancer Res., September 15, 2006; 66(18): 8949 - 8953.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
J M Garcia, R Rodriguez, G Dominguez, J M Silva, M Provencio, J Silva, A Colmenarejo, I Millan, C Munoz, C Salas, et al.
Prognostic significance of the allelic loss of the BRCA1 gene in colorectal cancer
Gut, December 1, 2003; 52(12): 1756 - 1763.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Matsumoto, T. Yoshida, and I. Okayasu
High Epithelial and Stromal Genetic Instability of Chromosome 17 in Ulcerative Colitis-associated Carcinogenesis
Cancer Res., October 1, 2003; 63(19): 6158 - 6161.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.